These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 23382880)
1. SUMO-1 modification on K166 of polyQ-expanded ataxin-3 strengthens its stability and increases its cytotoxicity. Zhou YF; Liao SS; Luo YY; Tang JG; Wang JL; Lei LF; Chi JW; Du J; Jiang H; Xia K; Tang BS; Shen L PLoS One; 2013; 8(1):e54214. PubMed ID: 23382880 [TBL] [Abstract][Full Text] [Related]
2. [Polyglutamine-expanded ataxin-3 is degraded by autophagy]. Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862 [TBL] [Abstract][Full Text] [Related]
3. The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability. Durcan TM; Kontogiannea M; Thorarinsdottir T; Fallon L; Williams AJ; Djarmati A; Fantaneanu T; Paulson HL; Fon EA Hum Mol Genet; 2011 Jan; 20(1):141-54. PubMed ID: 20940148 [TBL] [Abstract][Full Text] [Related]
4. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897 [TBL] [Abstract][Full Text] [Related]
5. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324 [TBL] [Abstract][Full Text] [Related]
6. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066 [TBL] [Abstract][Full Text] [Related]
7. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437 [TBL] [Abstract][Full Text] [Related]
8. Compromised mitochondrial complex II in models of Machado-Joseph disease. Laço MN; Oliveira CR; Paulson HL; Rego AC Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589 [TBL] [Abstract][Full Text] [Related]
9. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007 [TBL] [Abstract][Full Text] [Related]
10. Research on screening and identification of proteins interacting with ataxin-3. Shen L; Tang JG; Tang BS; Jiang H; Zhao GH; Xia K; Zhang YH; Cai F; Tan LM; Pan Q Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Jun; 22(3):242-7. PubMed ID: 15952105 [TBL] [Abstract][Full Text] [Related]
11. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein. Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213 [TBL] [Abstract][Full Text] [Related]
12. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100 [TBL] [Abstract][Full Text] [Related]
13. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3. Haacke A; Broadley SA; Boteva R; Tzvetkov N; Hartl FU; Breuer P Hum Mol Genet; 2006 Feb; 15(4):555-68. PubMed ID: 16407371 [TBL] [Abstract][Full Text] [Related]
14. Polyglutamine expansion of ataxin-3 alters its degree of ubiquitination and phosphorylation at specific sites. Kristensen LV; Oppermann FS; Rauen MJ; Hartmann-Petersen R; Thirstrup K Neurochem Int; 2017 May; 105():42-50. PubMed ID: 28065793 [TBL] [Abstract][Full Text] [Related]
15. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease. Matos CA; de Macedo-Ribeiro S; Carvalho AL Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957 [TBL] [Abstract][Full Text] [Related]
16. PolyQ-expanded ataxin-3 interacts with full-length ataxin-3 in a polyQ length-dependent manner. Jia NL; Fei EK; Ying Z; Wang HF; Wang GH Neurosci Bull; 2008 Aug; 24(4):201-8. PubMed ID: 18668148 [TBL] [Abstract][Full Text] [Related]
17. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD. Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414 [TBL] [Abstract][Full Text] [Related]
18. Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Jung J; Xu K; Lessing D; Bonini NM Hum Mol Genet; 2009 Dec; 18(24):4843-52. PubMed ID: 19783548 [TBL] [Abstract][Full Text] [Related]
19. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance. Li X; Liu H; Fischhaber PL; Tang TS Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252 [TBL] [Abstract][Full Text] [Related]
20. miR-25 alleviates polyQ-mediated cytotoxicity by silencing ATXN3. Huang F; Zhang L; Long Z; Chen Z; Hou X; Wang C; Peng H; Wang J; Li J; Duan R; Xia K; Chuang DM; Tang B; Jiang H FEBS Lett; 2014 Dec; 588(24):4791-8. PubMed ID: 25451224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]